Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presatovir in lung transplant recipients with RSV infection
NL-OMON43361Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Presatovir with Placebo (2 arms). Primary endpoints: Time-weighted average change in log10 viral load from baseline through Day 7 and Time-weighted average change in log10 viral load through Day 7 in early symptom subgroup. Started Jan 2017; status: active, not recruiting.
02
Drugs
presatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON43361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43361.